trending Market Intelligence /marketintelligence/en/news-insights/trending/a3b_1aya4sremrftqiutpg2 content esgSubNav
In This List

Viking Therapeutics closes $63.3M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Viking Therapeutics closes $63.3M common stock offering

Viking Therapeutics Inc. closed its underwritten public offering of 12,650,000 common shares at $5 apiece with gross proceeds of about $63.3 million.

The shares sold included 1,650,000 shares sold pursuant to the full exercise of underwriters' overallotment option to buy additional shares.

Viking plans to use the net proceeds for continued development of its clinical programs and for general research and development, working capital and general corporate purposes.

William Blair & Co. LLC acted as sole book-running manager and Maxim Group LLC and Roth Capital Partners acted as co-managers for the offering. H.C. Wainwright & Co. acted as a financial adviser for the offering.